Abstract:At the Washington "2nd International Workshop on Genotoxicity Testing" (25-26 March 1999) current methodologies and data for the in vitro micronucleus test were reviewed. As a result, guidelines for the conduct of specific aspects of the protocol were developed. Agreement was achieved on the following topics: choice of cells, slide preparation, analysis of micronuclei, toxicity, use of cytochalasin-B, number of doses, and treatment/harvest times [Environ. Mol. Mutagen. 35 (2000) 167]. Because there were a number of important in vitro micronucleus validation studies in progress, it was not possible to design a definitive, internationally harmonized protocol at that time. These studies have now been completed and the data were reviewed at the Plymouth "3rd International Workshop on Genotoxicity Testing" (28-29 June 2002). Data from studies coordinated by the French Society of Genetic Toxicology, Japanese collaborative studies, European pharmaceutical industry validation studies, along with data from Lilly Research Laboratories were used to prepare conclusions on the main aspects of the in vitro micronucleus protocol. In this paper, the consensus agreements on the protocol for performing the in vitro micronucleus assay are presented. The major recommendations concern: 1. Demonstration of cell proliferation: both cell lines and lymphocytes can be used, but demonstration of cell proliferation in both control and treated cells is compulsory for the acceptance of the test. 2. Assessment of toxicity and dose range finding: assessment of toxicity should be performed by determining cell proliferation, e.g. increased cell counts (CC) or population doubling (PD) without cytochalasin-B, or e.g. cytokinesis-block proliferation index with cytochalasin-B; and by determining other markers for cytotoxicity (confluency, apoptosis, necrosis) which can provide valuable additional information. 3. Treatment schedules for cell lines and lymphocytes. 4. Choice of positive controls: without S9-mix both a clastogen (e.g. mitomycin C or bleomycin) and an aneugen (e.g. colchicine) should be included as positive controls and a clastogen that requires S9 for activity when S9-mix is used (e.g. dimethylnitrosamine, or cyclophosphamide in those cell types that cannot activate this agent directly). 5. Duplicate cultures and number of cells to be scored. 6. Repeat experiments: in lymphocytes, for each experiment blood from 2 different healthy young and non-smoking donors should be compared. In cell lines, the experiments need only to be repeated if the first one is negative. 7. Statistics: statistical significance should not be the sole factor for determining positive results. Biological meaning should serve as a guideline. Examples of statistical analyses are given.

High throughput image cytometry micronucleus assay to investigate the presence or absence of mutagenic effects of cold physical plasma

A multi-biomarker micronucleus assay using imaging flow cytometry

Proteomic Profiling for Cellular Responses to Different Concentrations of N-Methyl-N '-Nitro-n-nitrosoguanidine

Altered Expression of Zinc Finger Proteins, ADAMs, and Integrin‐related Proteins Following Treatment of Cultured Human Cells with a Low Concentration of N‐methyl‐N′‐nitro‐N‐nitrosoguanidine

A Nonclinical Safety Evaluation of Cold Atmospheric Plasma for Medical Applications: The Role of Genotoxicity and Mutagenicity Studies

An Automated, Single Cell Quantitative Imaging Microscopy Approach to Assess Micronucleus Formation, Genotoxicity and Chromosome Instability

Micronucleus Assay: The State of Art, and Future Directions

On the Mechanism of Plasma Inducing Cell Apoptosis

Genotoxic and Mutagenic Properties of Atmospheric Pressure Plasma Jet on Human Liver Cell Line L02

Inter-laboratory automation of the in vitro micronucleus assay using imaging flow cytometry and deep learning

An Evaluation Of Anti-Oxidative Protection For Cells Against Atmospheric Pressure Cold Plasma Treatment

Some new methodological aspects of the hen's egg test for micronucleus induction (HET-MN)

Systemic Study on the Safety of Immuno-Deficient Nude Mice Treated by Atmospheric Plasma-Activated Water

Gas Flow-Dependent Modification of Plasma Chemistry in μAPP Jet-Generated Cold Atmospheric Plasma and Its Impact on Human Skin Fibroblasts

Development of an automatable micro-PCC biodosimetry assay for rapid individualized risk assessment in large-scale radiological emergencies

Report from the in vitro micronucleus assay working group

Revealing low-temperature plasma efficacy through a dose-rate assessment by DNA damage detection combined with machine learning models

Assessment of Cytotoxicity and Genotoxicity of Plasma-Treated Perfluorooctanesulfonate Containing Water Using In Vitro Bioassays

Quantitative Evaluation of DNA Damage Caused by Atmospheric and Room-Temperature Plasma(artp) and Other Mutagenesis Methods Using a Rapid Umu-Microplate Test Protocol for Microbial Mutation Breeding

Genotoxicity of a New Type of Non-Pollutant Mutagen, Low-Temperature Air Plasma

Automation of the in vitro micronucleus and chromosome aberration assay for the assessment of the genotoxicity of the particulate and gas–vapor phase of cigarette smoke